TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05886920: A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Sponsor: D3 Bio (Wuxi) Co., Ltd · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 67 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$2,591,820

Rescue Site Savings

+$1,727,880

Unlock Full NCT05886920 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05886920 Rescue Dossier →